Introduction
In the 196Os, the first evidence was obtained at the Max-Planck-Institute in Freiburg that lysolecithins, as a consequence of their high affinity to the cell membrane, not only cause changes in permeability (7, 16) , but are also catalysts in more complex cellular events. Synthetic (ether)-lysolecithins have been shown to be capable of influencing the mammalian body's own immune system (13). The effects obtained were structurally dependent. (Ether)-lysolecithins with long-chain alkyl residues (Cl6 and longer) led to immunostimulation.
Those with short-chain alkyl chains (C,, and shorter), led to immunosuppression.
The lack of (ether)-cleaving enzymes in carcinomas (17) was particularly interesting because of the possible use of (ether)-lysolecithins in the therapy of malignant tumors. This finding led to the hypothesis that (ether)-lysolecithins could be metabolized in normal cells, but not in malignant tissues. Based on differences in the enzyme content of neoplastic cells and normal cells, selective activity of the (ether)-lysolecithins towards tumor cells might be expected. In 1982, we started our investigations on the antitumor efficacy of phospholipids and analogs.
From (ether)-lysolecithins to alkylphosphocholines
Numerous studies have shown that 1-0-octadecyl-2-O-methyl-rut-glycero-3-phosphocholine inhibits the growth of methyl nitrosourea induced breast carcinomas in the rat. Surprisingly, the effect of these substances was not very selective (3). Therefore, the importance of the (ether)-cleaving enzyme as a selective detoxifying agent in normal cells was put in doubt. It was the aim of the present investigations to determine through systematic analysis of the metabolism of structurally modified (ether)-lysolecithins which structures might be selective. The study was expected to provide information on the minimal structural requirements for antitumor efficacy and, if possible, on which of these elements were responsible for selectivity. Our investigations were the first to discover a correlation between chemical structure, antitumor efficacy and selectivity. Of major importance for these investigations was the development of simple methods for the preparation of lysolecithins and analogs (6, 7, 8, 2 1).
H. EIBL AND C. UNGER It follows from Figure 2 that 1-palmitoyl-sn-3-glycero-phosphocholine (I) in microsomes derived from rat livers can, in the presence of oleoyl-CoA, be rapidly transformed into 1 -palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (I) and thereby detoxified. 
corresponding
(ether)-lysolecithins, e.g. 1-O-octadecyl-sn-glycero-3-phosphocholine (II). As shown in Figure 3 , under the optimal acylating conditions worked out for l-palmitoylsn-3-glycero-phosphocholine (I), no product is formed with I-O-octadecyl-sn-glycero-3-phosphocholine in the presence ofoleoyl-CoA (15). (Ether)-lysolecithins are not substrates for acyl-CoA dependent acyltransferases. However, detoxification is still possible by means ofother enzymes. For instance (ether)-lysolecithins (II) can be cleaved by 0-alkylglycerol monooxygenases or possibly via other acylating enzyme systems of the cell. We have, however, found enzymes which can detoxify 1-O-octadecyl-sn-glycero-3-phosphocholine in the absence of acyl-CoA. The enzymes are transesterases which transfer fatty acids from inositolphosphatides into the 2-position of (ether)-lysolecithins (15). These results are summarized in the deacylation-reacylation cycles for 1,2-diacyl-sn-glycero-3-phosphocholine and l-0-alkyl-2-acyl-alkyl-sn-glycero-3-phosphocholine ( Figure 4 ). Both groups of substances are turned into the corresponding single-chain compounds by phospholipase A,. Reacylation, however, takes place via various enzymes and with different cosubstrates.
In comparison to the (ester)-and (ether)-lysolecithins with free hydroxyl groups in the sn-2-glycerol position which can be acylated, Migration distance (k?fl substrate for 0-alkylglycerol monooxygenases.
We were able to prove this with newly developed methods (10, 11, 20) . The difference in the enzyme contents of tumor compared to normal cells cannot lead to a selective destruction of tumor tissue because 1 -O-octadecyl-2-0-methyl-sn-glycero-3-phosphocholine and the enantiomer 3-O-octadecyl-2-O-methylsn-glycero-1-phosphocholine are lacking the necessary substrate properties for O-alkylglycerol monooxygenases.
The selective activity that has been discussed in connection with differences in the enzyme content of tumor and normal cells for 0-alkylglycerol monooxygenases (2, 13) has not received experimental confirmation ( 18). From our experimental findings on the substrate properties of these substances, on their metabolism in cell cultures and in various organs, including rat tumors, it is possible to say that it is these missing substrate properties for alkylglycerol monooxygenases that are the critical requirements for tumor growth inhibition produced by these compounds. Only 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine has antineoplastic properties and, at the same time, is a marginal substrate for phospholipase C and D. In addition, a transfer of phosphocholine to diacylglycerol is observed ( Figure 5 ). The analogous compound with an enlarged distance between phosphate and trimethylammonia (IV), as shown in Figure 6 , has no substrate properties for phospholipid metabolizing enzymes and is inactive.
Substance V, 1-O-octadecyl-propandiol-3-phosphocholine is a substrate for 0-alkylglycerol monooxygenase and can therefore be detoxified. Our prediction from these observations is that the minimal structural elements for antineoplastic activity are given by an alkanol of chain length Cl6 to Cl8 attached to phosphocholine. The cells were incubated with labelled hexadecylphospho-('%)-choline and prepared as described in Figure 5 . Instead ofthe acidic system, a developing solvent system of chloroform/methanol/250/, ammonia 50 : 50 : 5 (by volume) was used. Increasing amounts of 1,2-(diacyl)-lecithin were formed in a time-dependent manner which occurred through a direct transfer of the phosphocholine group to diacylglycerol (see schematic representation).
octadecyl-2-0-methyl-rac-glycero-3-phosphocholine, hexadecylphosphocholine is a marginal substrate for phospholipase C and D (Figure 8 ) and also antineoplastically effective. On the other hand, hexadecylphospho-(N,N,N-trimethyl)-butanolamine is lacking the substrate properties for the necessary phospholipases mentioned.
In animal experiments, it has been ineffective against chemically induced, autochthonous mammary carcinomas. This demonstrates that phosphocholine is a necessary prerequisite ofantineoplastic activity in alkylphosphocholines.
Surprisingly, in the chemically induced mammary carcinoma models mentioned, hexadecylphosphocholine is superior to l-0-octadecyl-2-0-methyl-rat-glycero-3-phosphocholine.
For the first time, complete remissions were achieved in these difficult to treat models (9, 14) . These recent experiments prove the tumoricidal activity of hexadecylphosphocholine, whereas only a tumorostatic activity could be shown for l-Ooctadecyl-2-0-methyl-rac-glycero-3-phosphocholine.
The lack of bone marrow toxicity is useful for the long-term administration of this drug. The activity of hexadecylphosphocholine is exemplified by its effect on the dimethylbenzanthracene-induced mammary carcinoma model. Figure 9 illustrates the activity of orally administered hexadecylphosphocholine versus a single, maximally tolerated intravenous injection of cyclophosphamide in tumor bearing rats. Cyclophosphamide shows a slight reduction in tumor weight after a period of 7 days compared to the controls. Hexadecylphosphocholine, on the other hand, causes complete remission after 20 days. The effect of hexadecylphosphocholine is also independent of the size of the original tumor. In all experiments to date, we have achieved complete remissions, independent of the original tumor size. 
